Accéder au contenu
Merck

Effect of RTKN on progression and metastasis of colon cancer in vitro.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie (2015-09-10)
Guo-Qiang Qu, Yun-Min Lu, Yuan-Fei Liu, Yuan Liu, Wei-Xiong Chen, Xiao-Hong Liao, Wu-Ming Kong
RÉSUMÉ

Like many epithelial-derived cancers, colon cancer results from a multistep tumorigenic process. However, the detailed mechanisms involved in colon cancer formations are poorly characterized. In the present study, we investigated the role of RTKN in colon cancer and explored underlying mechanisms. The results showed that RTKN expression was significantly increased in colon cancer tissues when compared with the adjacent tissues of patients in Shanghai People's hospital and in TCGA independent dataset. Furthermore, silencing of RTKN inhibited cell proliferation, migration, invasion, and arrested cell cycle at G1 phase in LOVO cells. Bioinformatics analysis demonstrated that DNA replication and cell cycle were involved in the regulation of RTKN. MCM2/3/5, CDK1/2 and PCNA expression had a direct relationship with the reduction of RTKN. RTKN could affect the proliferation and metastasis of colon cancer by reducing expression of MCM2/3/5, CDK1/2 and PCNA, suggesting that RTKN was a potential target for treating colon cancer.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Iode, ≥99.99% trace metals basis
Sigma-Aldrich
Iode, 99.999% trace metals basis
Sigma-Aldrich
Iode, anhydrous, beads, −10 mesh, 99.999% trace metals basis
Sigma-Aldrich
MISSION® esiRNA, targeting human RTKN